Compare PBK & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBK | PLUR |
|---|---|---|
| Founded | N/A | 2001 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 25.5M |
| IPO Year | 2024 | 2001 |
| Metric | PBK | PLUR |
|---|---|---|
| Price | $0.47 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 556.5K | 15.9K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | N/A | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $0.42 | $1.45 |
| 52 Week High | $0.86 | $5.48 |
| Indicator | PBK | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 47.81 |
| Support Level | $0.43 | $1.56 |
| Resistance Level | $0.61 | $1.86 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 18.22 | 56.43 |
PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.